Fig. 1: CFI-400945 exhibits potent anti-tumor activities in DLBCL cells. | Cell Death & Disease

Fig. 1: CFI-400945 exhibits potent anti-tumor activities in DLBCL cells.

From: Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma

Fig. 1

a Three representative DLBCL cell lines LY1, LY8, and LY3 were treated with CFI-400945 at various concentrations after 24, 48, 72, or 96 h, respectively. Cell viability was assessed by CCK-8. b LY1, LY8, and LY3 cells were treated with increasing doses of CFI-400945 for 48 h. Apoptosis was measured by flow cytometry analysis. c The protein levels of cleavage products of PARP were detected in LY1, LY8, and LY3 cells after treatment with CFI-400945 for 48 h. Data are shown as the mean ± SD, n = 3. **P < 0.01, ***P < 0.001.

Back to article page